Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Karyopharm Therapeutics (KPTI) over the last 9 years, with Q4 2025 value amounting to $12.6 million.

  • Karyopharm Therapeutics' Interest Expenses rose 1262.94% to $12.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $45.8 million, marking a year-over-year increase of 2251.88%. This contributed to the annual value of $45.8 million for FY2025, which is 2251.88% up from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Interest Expenses stood at $12.6 million, which was up 1262.94% from $11.0 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Interest Expenses' 5-year high stood at $12.6 million during Q4 2025, with a 5-year trough of $5.0 million in Q2 2021.
  • Moreover, its 5-year median value for Interest Expenses was $6.5 million (2022), whereas its average is $7.9 million.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Interest Expenses plummeted by 2599.88% in 2021, and later surged by 8746.91% in 2024.
  • Over the past 5 years, Karyopharm Therapeutics' Interest Expenses (Quarter) stood at $7.9 million in 2021, then decreased by 25.88% to $5.9 million in 2022, then rose by 5.49% to $6.2 million in 2023, then surged by 80.48% to $11.2 million in 2024, then rose by 12.63% to $12.6 million in 2025.
  • Its last three reported values are $12.6 million in Q4 2025, $11.0 million for Q3 2025, and $11.2 million during Q2 2025.